Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose

• Status: Unknown status
• Trial end date: 2006-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to analyze the effect of Zymar and Vigamox on ocular surface bacteria. We believe that Zymar will eradicate more ocular surface bacteria than Vigamox.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Ophthalmic Consultants of Boston
• Collaborator: Allergan
• Treatments: Anti-Bacterial Agents; Antibiotics, Antitubercular; Disinfectants; Fluoroquinolones; Gatifloxacin; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination; Ophthalmic Solutions; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• Male or female 25 years of age or older

• Informed consent

• Likely to complete the entire course of the study

Exclusion Criteria:

• Contraindications or known sensitivity to any component of the study medications

• A subject on oral or topical antibiotics

• A subject that has a condition (i.e. an uncontrolled systemic disease) or is in a situation which, in the investigator's opinion, may put the subject at significant risk, may confound the trial results, or may interfere significantly with the subject's participation in the trial.

• Monocular subjects

• Contact lens wearers

• Subjects who regularly take eyedrops other than preservative free artificial tears

• A subject with an eye infection